For a report overview of this report please contact sara.peerun@visiongain.com
(+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/Report/2112/Clinical-Trial-Supply-and-Logistics-Market-for-Pharma-2018-2028
In MakroCare whitepaper, we have compiled and simplified some of these new policies, revisions, regulatory amendments from registration, labeling, safety reporting, renewal, publishing /eCTD submission of last year and forthcoming years.
The revision of the Quality System Regulation [QSR] (21CFR 820) which was a priority set in FDA’s Spring unified agenda also made it to the FDA’s Fall unified agenda published in October 2018. The revision will replace the existing regulation in an effort to stay modernized and harmonized with the International standard ISO 13485:2016...
In MakroCare whitepaper, we have compiled and simplified some of these new policies, revisions, regulatory amendments from registration, labeling, safety reporting, renewal, publishing /eCTD submission of last year and forthcoming years.
The revision of the Quality System Regulation [QSR] (21CFR 820) which was a priority set in FDA’s Spring unified agenda also made it to the FDA’s Fall unified agenda published in October 2018. The revision will replace the existing regulation in an effort to stay modernized and harmonized with the International standard ISO 13485:2016...
Pharmaceutical Filtration Overview with CAGR of 11.8% over the forecast perio...Research Nester
Pharmaceutical Filtration is the most important process of pharmaceutical industry and Entire information included in PPT Session, In this PPT included Pharmaceutical solution and full Information & forecast period 2017-2024.,
Global orphan drug market outlook 2018Rajesh Sarma
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Competitive Landscape
The power of marketing & sales collaboration for omnichannel engagementAcross Health
Reimagine the role of customer-facing teams, guided by Beverly Smet (SVP Global Accounts) and Christoph Schmidt (Head of Strategy).
The major takeaways of this webinar include:
• The new commercial model in biopharma: a cross-functional, customer-centric ecosystem
• Roadmap to data-driven omnichannel customer engagement vs the current reality in biopharma
• Case study with demonstrated impact on omnichannel engagement through marketing & sales collaboration
• Key steps for omnichannel engagement success
Watch the recorded webinar and access the full deck on our website: https://bit.ly/2PBTOST
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
India IVD (Instruments & Reagents) Market, Share, Registration, Regulations &...iGATE RESEARCH
iGATE Research has released a research report on “India IVD (Instruments & Reagents) Market, Share, Registration, Regulations & Classification of IVD and Key Players Analysis - Forecast to 2025”
Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=154
Contact US
iGATE Research PVT LTD
Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com
This powerpoint presentation was made by Jennifer McEntire, Ph.D, with the Institute of Food Technologists to the joint FDA/FSIS meetings held in Washington D.C. on December 9 & 10 regarding traceability for produce.
Availability of essential medicines in Hungary (2017)Arete-Zoe, LLC
This report analyzes availability of essential medicines as defined in the World Health Organization (WHO) Essential List Medicines (Report of the WHO Expert Committee) in Hungary. The WHO list of essential medicines contains most effective and safe medicines needed to meet the most important needs in health systems and is frequently used by countries to create their own national lists. Without these drugs, some conditions will not be able to receive optimal therapy. Availability gap represents serious public health concern. Expert Committee of the World Health Organization selects Essential Medicines Lists in accordance with approved procedures. The Committee evaluates the scientific evidence on the basis of the comparative effectiveness, safety and cost-effectiveness of the medicines.
This is a Dean's Case Competition project in Som-Binghamton University. I did it with my team in Spring 2014 to present our the overall situation of Medtronic Inc.
Madison Park Group Life Sciences Software Market Update H2 2018Madison Park Group
We are pleased to present our review of the life sciences software market for the first half of 2018.
Madison Park Group is a unique investment banking firm that takes a "strategy first" approach to advising software companies. Our partners have developed and advised numerous successful companies as operators, investors and investment bankers.
Rohan Khanna and Jon Adler spearhead the firm's efforts in the life sciences software market.
Pharmaceutical Filtration Overview with CAGR of 11.8% over the forecast perio...Research Nester
Pharmaceutical Filtration is the most important process of pharmaceutical industry and Entire information included in PPT Session, In this PPT included Pharmaceutical solution and full Information & forecast period 2017-2024.,
Global orphan drug market outlook 2018Rajesh Sarma
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Competitive Landscape
The power of marketing & sales collaboration for omnichannel engagementAcross Health
Reimagine the role of customer-facing teams, guided by Beverly Smet (SVP Global Accounts) and Christoph Schmidt (Head of Strategy).
The major takeaways of this webinar include:
• The new commercial model in biopharma: a cross-functional, customer-centric ecosystem
• Roadmap to data-driven omnichannel customer engagement vs the current reality in biopharma
• Case study with demonstrated impact on omnichannel engagement through marketing & sales collaboration
• Key steps for omnichannel engagement success
Watch the recorded webinar and access the full deck on our website: https://bit.ly/2PBTOST
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
India IVD (Instruments & Reagents) Market, Share, Registration, Regulations &...iGATE RESEARCH
iGATE Research has released a research report on “India IVD (Instruments & Reagents) Market, Share, Registration, Regulations & Classification of IVD and Key Players Analysis - Forecast to 2025”
Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=154
Contact US
iGATE Research PVT LTD
Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com
This powerpoint presentation was made by Jennifer McEntire, Ph.D, with the Institute of Food Technologists to the joint FDA/FSIS meetings held in Washington D.C. on December 9 & 10 regarding traceability for produce.
Availability of essential medicines in Hungary (2017)Arete-Zoe, LLC
This report analyzes availability of essential medicines as defined in the World Health Organization (WHO) Essential List Medicines (Report of the WHO Expert Committee) in Hungary. The WHO list of essential medicines contains most effective and safe medicines needed to meet the most important needs in health systems and is frequently used by countries to create their own national lists. Without these drugs, some conditions will not be able to receive optimal therapy. Availability gap represents serious public health concern. Expert Committee of the World Health Organization selects Essential Medicines Lists in accordance with approved procedures. The Committee evaluates the scientific evidence on the basis of the comparative effectiveness, safety and cost-effectiveness of the medicines.
This is a Dean's Case Competition project in Som-Binghamton University. I did it with my team in Spring 2014 to present our the overall situation of Medtronic Inc.
Madison Park Group Life Sciences Software Market Update H2 2018Madison Park Group
We are pleased to present our review of the life sciences software market for the first half of 2018.
Madison Park Group is a unique investment banking firm that takes a "strategy first" approach to advising software companies. Our partners have developed and advised numerous successful companies as operators, investors and investment bankers.
Rohan Khanna and Jon Adler spearhead the firm's efforts in the life sciences software market.
Clinical trial is a medical research study performed on humans to check the safety and efficacy of drugs, devices and therapeutic products before they are finally launched in the market. Proper management of clinical trials has become a priority for hospitals, pharmaceutical companies and clinical research organizations (CRO).
Practice Management System Market Share and Size, 2018 to 2024Signitech
The global practice management system market size was valued at USD 6.9 billion in 2015. The industry is majorly driven by its competence to bring efficiency in healthcare delivery.
As of my last knowledge update in September 2021, the list of the top Contract Research Organizations (CROs) can vary depending on factors such as revenue, services offered, therapeutic areas of expertise, and global presence. The following list includes some of the prominent CROs based on their reputation, scale, and contributions to the clinical research industry:
IQVIA (formerly QuintilesIMS):
IQVIA is one of the largest CROs in the world, offering a wide range of services including clinical development, real-world evidence solutions, commercialization services, and consulting. They have a vast global network and expertise across various therapeutic areas.
PPD (Pharmaceutical Product Development):
PPD is known for its comprehensive clinical trial services, laboratory services, and real-world evidence solutions. They have a strong global presence and experience in managing trials of varying complexity.
Covance:
Covance, a subsidiary of LabCorp, is known for its extensive portfolio of drug development services including clinical development, central laboratory services, and market access solutions. They have experience in a broad range of therapeutic areas.
Syneos Health:
Syneos Health offers integrated solutions across clinical development, commercialization, and real-world evidence. They focus on helping clients navigate the entire drug development journey.
ICON:
ICON provides a variety of clinical research services, including consulting, clinical trial execution, laboratory services, and outcomes research. They have expertise in a wide array of therapeutic areas.
Parexel:
Parexel offers services ranging from clinical research and regulatory consulting to market access and commercialization. They are known for their global reach and innovative approach to clinical trials.
WuXi AppTec:
WuXi AppTec is a global company that provides a wide range of R&D services, including preclinical and clinical development, manufacturing, and regulatory services.
Medpace:
Medpace is known for its focused and customized approach to clinical trial management, particularly in the area of complex and specialized studies.
Celerion:
Celerion specializes in early-stage clinical research, with a focus on providing solutions for both small and large molecules.
Charles River Laboratories:
While Charles River Laboratories primarily focuses on preclinical research, they also offer a range of early-stage clinical development services.
Gynecological Devices Market Size, Share and Trend Analysis ReportSignitech
The global gynecological devices market size was valued at USD 8.9 billion in 2018. It is anticipated to exhibit a CAGR of 8.4% during the forecast period.
In vivo CRO Market Size, Share & Trends Analysis Report By Product Type, By GLP Type, By Indication (Diabetes, Obesity, Autoimmune/Inflammatory, CNS Conditions), And Segment Forecasts, 2019 - 2026
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Opportunity analysis of life science tools market in India - A srinivas sash...Srinivas Sashidhar
An analysis of the life science tools market in India and the market opportunity.
Please note this is a proprietary research on my views in a series of srinivas sashidhar's healthcare instinct. Your views and comments are welcome.
I am also open to individual assignments on market consulting in healthcare related markets.
You can follow my blog at https://kchsashi.blogspot.com/
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessFitking Fitness
"Feature:
• Intelligent Ergonomically Design Glute Builder Is A Must Have For Those Looking To Target Their Gluteal Muscles And Hamstrings With Precision.
• The Ability To Adjust The Starting Position, This Machine Allows For A More Targeted Workout That Is Tailored To Your Specific Needs.
• Spacious And Supportive Cushioned Seat Provide Added Comfort And Stability During Your Workout."
Get more information visit on:- www.fitking.in
Our mail I.D:-care@fitking.in, fitking.in@gmail.com
Call us at :- 9958880790, 9870336406, 8800695917
COVID-19 PCR tests remain a critical component of safe and responsible travel in 2024. They ensure compliance with international travel regulations, help detect and control the spread of new variants, protect vulnerable populations, and provide peace of mind. As we continue to navigate the complexities of global travel during the pandemic, PCR testing stands as a key measure to keep everyone safe and healthy. Whether you are planning a business trip, a family vacation, or an international adventure, incorporating PCR testing into your travel plans is a prudent and necessary step. Visit us at https://www.globaltravelclinics.com/
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
CANSA support - Caring for Cancer Patients' Caregivers
Clinical Trial Supply and Logistics Market for Pharma 2018-2028 pharmaceutical clinical trials drug supply
1. Page 67www.visiongain.com
Clinical Trial Supply and Logistics Market for Pharma 2018-
2028: Clinical Trial Manufacturing, Clinical Trial Logistics and
Distributions, Clinical Trial Supply Chain Management,
Clinical Trial Packaging, Clinical Trial Cold Chain Logistics
through inefficient planning. Planning supply networks can avoid costly delays with drugs not
reaching trial sites on time. In 2017, Visiongain estimates that trial sponsors spent $0.74bn on
clinical trial supply chain management services. Services in this sector are offered by many of the
companies that participate in other segments of the clinical trial supply and logistics market, as well
as specialist service providers, such as Fisher Clinical Services.
3.5.1 Clinical Trial Supply Chain Management Submarket Forecast
2017-2028
Growth in the clinical trial supply chain management submarket will be faster than that of the
clinical trial logistics and distribution submarket, Visiongain forecasts. Between 2017 and 2022, the
supply chain management submarket will grow with a CAGR of 7.4%, reaching $1.06bn by 2022
and $1.51bn by the end of 2028 (Table 3.14 and Figure 3.16). Later the revenue growth will be
less compared to the first half of the forecast period. Uptake of complex trial designs, such as
adaptive clinical trials and trials for stratified patient populations, will lead to more complicated
planning, in terms of supply chains and drug demand forecasting, Visiongain predicts.
Table 3.14 Clinical Trial Supply Chain Management Market:
Revenue Forecast ($bn), AGR (%) and CAGR (%), 2017-2028
2017 2018 2019 2020 2021 2022
Clinical Trial Suply
Chain Management
0.74 0.80 0.86 0.93 0.99 1.06
AGR % 7.8 8.1 7.3 6.9 7.0
CAGR 2017-2022 (%)
2023 2024 2025 2026 2027 2028
Clinical Trial Suply
Chain Management
1.11 1.18 1.24 1.30 1.40 1.51
AGR % 4.7 6.3 5.1 4.8 7.7 7.9
CAGR 2022-2028 (%)
7.4
6.1
Source: Visiongain 2018
2. Page 92www.visiongain.com
Clinical Trial Supply and Logistics Market for Pharma 2018-
2028: Clinical Trial Manufacturing, Clinical Trial Logistics and
Distributions, Clinical Trial Supply Chain Management,
Clinical Trial Packaging, Clinical Trial Cold Chain Logistics
Figure 4.17 Japanese Clinical Trial Supply and Logistics:
Drivers and Restraints, 2017-2028
be attracted to South Korea as a trial destination, as it offers lower cost trials but high regulatory
standards.
4.6 Clinical Trials Increasing Demand in Emerging National Markets
As of now, the four BRIC nations - the leading emerging pharmaceutical markets - accounts for just
8.6% of trials registered on ClinicalTrials.gov. However, these markets are growing in terms of
demand for clinical trials, as companies continue to take advantage of access to large, treatment-
naïve patient populations, low-cost trial management and access to growing pharmaceutical
markets. According to the Biopharma Cold Chain 2012 Sourcebook, growth of 65% growth in
clinical research will come from studies conducted in emerging market countries in 2017.
Outsourcing to local and global CROs will boost the clinical trial industries in those markets in the
coming 10 years.
However, challenges remain with clinical trial logistics for these markets. Most drugs for clinical
trials will be manufactured outside these countries, meaning that an understanding of local import
regulations is required. Misunderstanding of import regulations can lead to costly delays in trials,
as well as longer storage times while sponsors wait for drugs to clear customs. Longer storage
times are also the result of less established supplier networks, particularly for temperature-
The Japanese market is relatively
new, compared with the US and
EU, and the market is growing
faster
Leading global players have
established logistics networks in
Japan since 2007. Expansion in this
decade will provide an improved
network there
Domestic drug developers have
long pipelines, with many novel
biopharmaceuticals in
development
Increased off-shoring of clinical
trials to emerging Asian markets,
particularly China and South
Korea, will restrain logistics
demand.
Outsourcing is less common in
Japan than in other developed
markets and drug developers may
prefer to keep activities in-house
in this decade
Strict rules regarding quality and
control will restrain outsourcing
Drivers
Restraints
Source: Visiongain 2018
3. Page 169www.visiongain.com
Clinical Trial Supply and Logistics Market for Pharma 2018-
2028: Clinical Trial Manufacturing, Clinical Trial Logistics and
Distributions, Clinical Trial Supply Chain Management,
Clinical Trial Packaging, Clinical Trial Cold Chain Logistics
Figure 8.4 Catalent: Clinical Manufacturing Space by Region
(%), 2017
8.2.1.2 Strong Growth for Clinical Manufacturing Revenue
In September 2016, Catalent acquired Pharmatek, a clinical manufacturing and contract drug
development company that adds discovery-to-clinic drug development capabilities that expands
the company’s portfolio with advanced delivery technologies such as spray drying.
For the year 2015, Catalent’s DCS division revenue totalled $438.8m (Table 8.6), up 6.5%
compared to 2014. Since 2011, Catalent’s revenue is growing with a CAGR of 29.3%. In 2012,
Catalent acquired Aptuit which resulted in DCS revenue dramatic increase in 2013 - the acquisition
reportedly added $50m revenue in each of the first and second quarters of that year alone.
Catalent reports that, following the acquisition of Aptuit’s CTS division; it is the world’s second
largest manufacturer of clinical trial materials. There was an addition of Antibody Drug Conjugate
business when Catalent completed the acquisition of the Redwood BioScience business in
October 2014. Later in the next month, company extended particle engineering capabilities via the
acquisition of Micron Technologies. We believe our own internal innovation, supplemented by
current and future external partnerships and acquisitions, will continue to strengthen and extend
our leadership positions in the delivery and development of drugs, biologics and consumer health
America
57.5%
Europe
33.8%
Asia
Pacific
8.7%
Source: Catalent 2018, Visiongain 2018